 |
 Video: What is a Stock Split?
|
|
|
| Prelude Therapeutics is a clinical-stage oncology company built on a foundation of drug discovery to deliver precision cancer medicines to underserved patients. Co.'s primary candidates are designed to be oral, potent and selective inhibitors of protein arginine methyltransferase 5 (PRMT5). PRT811, Co.'s second clinical candidate, is a PRMT5 inhibitor that it has optimized for high brain exposure. PRT1419, Co.'s third clinical candidate, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1. PRT2527, Co.'s fourth clinical candidate, is designed to be a potent and selective Cyclin-dependent kinase 9 inhibitor. According to our Prelude Therapeutics stock split history records, Prelude Therapeutics has had 0 splits. | |
|
Prelude Therapeutics (PRLD) has 0 splits in our Prelude Therapeutics stock split history database.
Looking at the Prelude Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Prelude Therapeutics shares, starting with a $10,000 purchase of PRLD, presented on a split-history-adjusted basis factoring in the complete Prelude Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
09/28/2020 |
|
| End date: |
04/19/2024 |
|
| Start price/share: |
$27.79 |
|
| End price/share: |
$3.72 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-86.61% |
|
| Average Annual Total Return: |
-43.17% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1,338.34 |
|
| Years: |
3.56 |
|
|
|
|
|
